Literature DB >> 19860934

Gleason score and laterality concordance between prostate biopsy and prostatectomy specimens.

Kenneth G Nepple1, Terry L Wahls, Stephen L Hillis, Fadi N Joudi.   

Abstract

OBJECTIVES: Prostate biopsy involvement and Gleason score guide treatment decisions in prostate cancer. We evaluated concordance in Gleason score and laterality between biopsy and radical retropubic prostatectomy (RRP) specimens and factors that influenced this relationship.
MATERIALS AND METHODS: We reviewed 538 prostate cancer diagnoses at a Veterans Affairs medical center (2000-2005) to identify men with prostate biopsy and RRP specimens. During this time there was a move from limited (6 core) to extended (12 core) biopsy schemes. Discordance in Gleason score was defined as any change in Gleason score.
RESULTS: 152 men underwent RRP with biopsy showing Gleason < 7 in 56%, 7 in 36%, and > 7 in 8%. Biopsy involvement was unilateral in 59% and bilateral in 41%. Compared to the biopsy, RRP Gleason score was concordant in 76 (50%), higher in 51 (34%), and lower in 25 (16%). Bilateral involvement was concordant in 97%, while unilateral involvement was concordant in only 20%. Both Gleason score and laterality were concordant in only 26%. Gleason concordance was higher in those with 8 or more cores compared to < 8 cores taken (54% vs. 34%, p = 0.046), but concordance was not affected by age, PSA, prostate volume, or length of time from biopsy to RRP. During later years, concordance did not improve despite taking more cores.
CONCLUSIONS: Prostate biopsy underestimated prostatectomy Gleason score in 34% of men and bilateral involvement in 80% of those with unilateral disease on biopsy. Taking at least eight cores improves the accuracy of the prostate biopsy.

Entities:  

Mesh:

Year:  2009        PMID: 19860934     DOI: 10.1590/s1677-55382009000500007

Source DB:  PubMed          Journal:  Int Braz J Urol        ISSN: 1677-5538            Impact factor:   1.541


  6 in total

1.  Prospective evaluation of 18F-FACBC PET/CT and PET/MRI versus multiparametric MRI in intermediate- to high-risk prostate cancer patients (FLUCIPRO trial).

Authors:  Ivan Jambor; Anna Kuisma; Esa Kähkönen; Jukka Kemppainen; Harri Merisaari; Olli Eskola; Jarmo Teuho; Ileana Montoya Perez; Marko Pesola; Hannu J Aronen; Peter J Boström; Pekka Taimen; Heikki Minn
Journal:  Eur J Nucl Med Mol Imaging       Date:  2017-11-16       Impact factor: 9.236

2.  Radiomics and machine learning of multisequence multiparametric prostate MRI: Towards improved non-invasive prostate cancer characterization.

Authors:  Jussi Toivonen; Ileana Montoya Perez; Parisa Movahedi; Harri Merisaari; Marko Pesola; Pekka Taimen; Peter J Boström; Jonne Pohjankukka; Aida Kiviniemi; Tapio Pahikkala; Hannu J Aronen; Ivan Jambor
Journal:  PLoS One       Date:  2019-07-08       Impact factor: 3.240

3.  Secreted miR-153 Controls Proliferation and Invasion of Higher Gleason Score Prostate Cancer.

Authors:  Gloria Bertoli; Antonella Panio; Claudia Cava; Francesca Gallivanone; Martina Alini; Giulia Strano; Federico Molfino; Loredana Brioschi; Paola Viani; Danilo Porro
Journal:  Int J Mol Sci       Date:  2022-06-06       Impact factor: 6.208

4.  Advanced Imaging Analysis in Prostate MRI: Building a Radiomic Signature to Predict Tumor Aggressiveness.

Authors:  Anna Damascelli; Francesca Gallivanone; Giulia Cristel; Claudia Cava; Matteo Interlenghi; Antonio Esposito; Giorgio Brembilla; Alberto Briganti; Francesco Montorsi; Isabella Castiglioni; Francesco De Cobelli
Journal:  Diagnostics (Basel)       Date:  2021-03-26

5.  Is small prostate volume a predictor of Gleason score upgrading after radical prostatectomy?

Authors:  Mun Su Chung; Seung Hwan Lee; Dong Hoon Lee; Byung Ha Chung
Journal:  Yonsei Med J       Date:  2013-07       Impact factor: 2.759

Review 6.  Current status of biomarkers for prostate cancer.

Authors:  Vicki M Velonas; Henry H Woo; Cristobal G dos Remedios; Stephen J Assinder
Journal:  Int J Mol Sci       Date:  2013-05-24       Impact factor: 5.923

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.